12:00 AM
 | 
Dec 09, 2013
 |  BC Week In Review  |  Clinical News  |  Regulatory

Xtandi enzalutamide regulatory update

Germany's Institute for Quality and Efficiency in Healthcare (IQWiG) said Xtandi enzalutamide from Astellas has additional benefit over best supportive care (BSC) to treat hormone-relapsed, metastatic prostate cancer in patients whose disease has progressed on or after docetaxel therapy - its approved indication. IQWiG said...

Read the full 205 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >